Immunotech Biopharm Ltd
Immunotech Biopharm Ltd has a negative equity position of CNY -13.93 million, indicating a significant financial challenge, and a debt-to-equity ratio of -31.61, which suggests that the company is financed almost entirely by debt. The company's liquidity is rated as medium, with a current ratio of 0.35, which is below the typical threshold for financial health, indicating that the company may struggle to meet its short-term obligations. The company's profitability is weak, with a net loss of CNY -230.79 million and an operating loss of CNY -222.89 million, which is far below the industry median for profitability metrics. The return on assets is negative at -0.3828, and the return on equity is 16.571, which is unusually high given the negative equity, suggesting that the company is not effectively utilizing its assets to generate profit. Immunotech Biopharm Ltd's revenue is reported as CNY 0.0, indicating that the company is not currently generating revenue from its operations. The company's financial snapshot does not provide segment or geographic revenue breakdowns, so it is unclear where the company's exposure lies. The company's growth trajectory is not evident from the provided data, as there is no revenue history to analyze. The company's outlook for the current and next fiscal years is not provided, but the negative operating and net income suggest a challenging period ahead. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity challenges. The company's capital structure is heavily leveraged, with long-term debt of CNY 440.26 million, which could pose a significant financial risk if not managed effectively. There are no recent events or filings provided in the data to indicate any significant changes in the company's operations or financial status.
Business. Immunotech Biopharm Ltd is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biopharmaceutical products.
Classification. Immunotech Biopharm Ltd is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a classification confidence of 0.92.
- Immunotech Biopharm Ltd is experiencing significant financial distress, as evidenced by its negative equity and high debt-to-equity ratio.
- The company is not generating revenue and is reporting substantial operating and net losses, indicating poor profitability.
- The company's liquidity position is weak, with a current ratio of 0.35, which may hinder its ability to meet short-term obligations.
- The company's capital structure is heavily reliant on debt, which could pose a significant financial risk if not managed effectively.
- # RATIONALES
- {
- "margin_outlook_rationale": "The company's margin outlook is negative due to its substantial operating and net losses, indicating poor cost management and pricing power.",
- "rd_outlook_rationale": "The company's R&D outlook is uncertain as there is no specific data provided on R&D expenditures or projects.",
- Net cash is negative after subtracting total debt.